Progestins for Symptomatic Endometriosis: Results of Clinical Studies
article
OA: closed
CC0
⤵ 14 in-corpus citations
AI-generated summary
Progestins are safe, effective, and well-tolerated first-line medical treatments for symptomatic endometriosis, despite challenges in comparative analysis due to study limitations.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Progestins, which are synthetic progestational compounds, have been used in the management of symptomatic endometriosis, both as primary therapy and as an adjunct to surgery. Several oral compounds have been used for this purpose, and different degrees of benefits have been shown. The lack of a standardized instrument to evaluate painful symptoms makes comparative analysis very difficult. We performed a systematic search of the Pubmed database from January 1980 to January 2015. The database used the term “endometriosis” as the relevant medical subject heading; selected sub- headings were “progestins”, “medical therapy”, “review” and “randomized controlled trials”, “controlled trials”, “case-control studies”, and “descriptive studies”. We aimed to review all available trials in order to investigate the medical treatment of endometriosis solely with progestins, with special attention to pharmacodynamic activity. The drugs studied were cyproterone acetate, norethisterone acetate, medroxyprogesterone acetate, levonorgestrel, etonogestrel, dienogest, and selective progesterone receptor modulators. However, it is very difficult to reach a definitive conclusion because most trials were small, retrospective, and uncontrolled. Nevertheless, it is clear that progestins are generally safe, effective, and well tolerated and should be considered as the first line of medical treatment in symptomatic endometriosis provided the patients have no desire for pregnancy. Keywords: Cyproterone acetate, dienogest, dysmenorrhea, endometriosis, etonogestrel, levonorgestrel, medroxyprogesterone acetate, norethisterone acetate, pelvic pain, progestins.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (14)
- Endometriosis Research: From Bench to Bedside 2022
- Current status and challenges of drug development for hormonal treatment of endometriosis: a systematic review of randomized control trials 2022
- Deep Endometriosis and Infertility: What Is the Impact of Surgery? 2022
- Medical and surgical interventions to improve the quality of life for endometriosis patients: a systematic review 2021
- Laparoscopic treatment of deep endometriosis with a diode laser: our experience 2021
- Genetic Characterization of Endometriosis Patients: Review of the Literature and a Prospective Cohort Study on a Mediterranean Population 2020
- Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study 2019
- Genetics of endometriosis: a comprehensive review 2019
- <p>Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study</p> 2019
- Reviewing the role of progesterone therapy in endometriosis 2018
- Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature 2017
- Adenomyosis: a systematic review of medical treatment 2016
- Current and Future Medical Treatment of Adenomyosis 2016
- Multidimensional assessment of pain in women with endometriosis: Preliminary results of the experience in Cagliari 2016
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK